Oncotarget’s Top 10 Papers Published in 2023 (Crossref Data) | Oncotarget



February 14, 2024

  • Share
  • Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month, Crossref identifies a list of the most popular Oncotarget papers based on the number of times a DOI is successfully resolved. Below are Crossref’s Top 10 Oncotarget DOIs of papers published in 2023. 10: Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC) DOI: https://doi.org/10.18632/oncotarget.28355 Authors: Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nathan 9: Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer DOI: https://doi.org/10.18632/oncotarget.28353 Authors: Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Yohei Sasaki, Koki Kawakami, Ryoji Hyakudomi, Tetsu Yamamoto, and Yoshitsugu Tajima 8: Crosstalk between triple negative breast cancer and microenvironment DOI: https://doi.org/10.18632/oncotarget.28397 Authors: Karly Smrekar, Artem Belyakov, and Kideok Jin 7: Systemic AL amyloidosis: current approach and future direction DOI: https://doi.org/10.18632/oncotarget.28415 Authors: Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain 6: Deciphering the mechanisms of action of progesterone in breast cancer DOI: https://doi.org/10.18632/oncotarget.28455 Authors: Gaurav Chakravorty, Suhail Ahmad, Mukul S. Godbole, Sudeep Gupta, Rajendra A. Badwe, and Amit Dutt 5: Targeting cellular respiration as a therapeutic strategy in glioblastoma DOI: https://doi.org/10.18632/oncotarget.28424 Authors: Enyuan Shang, Trang Thi Thu Nguyen, Mike-Andrew Westhoff, Georg Karpel-Massler, and Markus D. Siegelin 4: Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells DOI: https://doi.org/10.18632/oncotarget.28382 Author: Mikhail V. Blagosklonny 3: The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy DOI: https://doi.org/10.18632/oncotarget.28354 Authors: Anqi Shao and David M. Owens 2: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss DOI: https://doi.org/10.18632/oncotarget.28376 Authors: Maroun Bou Zerdan, Prashanth Ashok Kumar, Elio Haroun, Nimisha Srivastava, Jeffrey Ross, and Abirami Sivapiragasam 1: Using cancer proteomics data to identify gene candidates for therapeutic targeting DOI: https://doi.org/10.18632/oncotarget.28420 Authors: Diana Monsivais, Sydney E. Parks, Darshan S. Chandrashekar, Sooryanarayana Varambally, and Chad J. Creighton About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchCell ScienceMolecular Biology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.